Sign In  |  Register  |  About Walnut Creek Guide  |  Contact Us

Walnut Creek, CA
September 01, 2020 1:43pm
7-Day Forecast | Traffic
  • Search Hotels in Walnut Creek Guide

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

Adicet Bio to Present Preclinical Data from Allogeneic Gamma Delta T Cell Pipeline Programs at The Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

Adicet to Host R&D Webcast Event on Thursday, November 10, 2022 at 9:00am EST

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing first in class, allogeneic chimeric antigen receptor (CAR) and adaptor (CAd) gamma delta T cell therapies today announced four preclinical abstract poster presentations at the upcoming Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting taking place November 8-12, 2022 in Boston, MA.

Poster Presentations:

Abstract Title: Innate-Enhanced Chimeric Adaptors (CAd): A Newly-Described Approach for Augmenting Potency of γδ T Cell Immunotherapy

Poster/Abstract Number: 198

Presenting Author: Marissa Herrman, Ph.D.

Date/Time: November 11, 2022 from 9:00am – 9:00pm EST

Title: Preclinical Discovery and Characterization of Allogeneic anti-PSMA γδ CAR T Therapy for Prostate Cancer

Poster/Abstract Number: 203

Presenting Author: Nitya S. Ramadoss, Ph.D.

Date/Time: November 10, 2022 from 9:00am – 9:00pm EST

Abstract Title: Allogeneic “off-the-shelf” γδ T cells modified with CD27- containing CAR for targeting CD70+ cancers

Poster/Abstract Number: 246

Presenting Author: Kevin P. Nishimoto, Ph.D.

Date/Time: November 11, 2022 from 9:00am – 9:00pm EST

Abstract Title: Preclinical Discovery and Evaluation of Allogeneic “off-the-shelf” γδ CAR T Cells Targeting B7-H6+ Tumors

Poster/Abstract Number: 247

Presenting Author: Kevin P. Nishimoto, Ph.D.

Date/Time: November 10, 2022 from 9:00am – 9:00pm EST

The abstracts will be available in a Journal for ImmunoTherapy of Cancer (JITC) supplement, which will be published on Monday, November 7 at 8:00am EST on www.sitcancer.org.

R&D Webcast

Adicet will host an R&D webcast presentation on Thursday, November 10, 2022 at 9:00am EST to provide an overview of its R&D pipeline.

About Adicet Bio, Inc.

Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic chimeric antigen receptor (CAR) and adaptor (CAd) gamma delta T cell therapies engineered to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients. For more information, please visit our website at http://www.adicetbio.com.

Contacts

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Copyright © 2010-2020 WalnutCreekGuide.com & California Media Partners, LLC. All rights reserved.